{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:37Z","timestamp":1778733037788,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2015,1]]},"abstract":"Malignant pleural mesothelioma (MPM<\/jats:styled-content>) is a rare and highly aggressive neoplasm that arises from the pleural, pericardial, or peritoneal lining. Although surgery, chemotherapy, radiotherapy, and combinations of these therapies are used to treat MPM<\/jats:styled-content>, the median survival of such patients is dismal. Therefore, there is a compelling need to develop novel therapeutics with different modes of action. Ganglioside GM<\/jats:styled-content>2 is a glycolipid that has been shown to be overexpressed in various types of cancer. However, there are no published reports regarding the use of GM<\/jats:styled-content>2 as a potential therapeutic target in cases of MPM<\/jats:styled-content>. In this study, we evaluated the efficacy of the anti\u2010GM<\/jats:styled-content>2 antibody BIW<\/jats:styled-content>\u20108962 as an anti\u2010MPM<\/jats:styled-content> therapeutic using in vitro<\/jats:italic> and in vivo<\/jats:italic> assays. Consequently, the GM<\/jats:styled-content>2 expression in the MPM<\/jats:styled-content> cell lines was confirmed using flow cytometry. In addition, eight of 11 cell lines were GM<\/jats:styled-content>2\u2010positive (73%), although the GM<\/jats:styled-content>2 expression was variable. BIW<\/jats:styled-content>\u20108962 showed a significant antibody\u2010dependent cellular cytotoxicity activity against the GM<\/jats:styled-content>2\u2010expressing MPM<\/jats:styled-content> cell line MSTO<\/jats:styled-content>\u2010211H, the effect of which depended on the antibody concentration and effector\/target ratio. In an in vivo<\/jats:italic> orthotropic mouse model using MSTO<\/jats:styled-content>\u2010211H cells, BIW<\/jats:styled-content>\u20108962 significantly decreased the incidence and size of tumors. Additionally, the GM<\/jats:styled-content>2 expression was confirmed in the MPM<\/jats:styled-content> clinical specimens. Fifty\u2010eight percent of the MPM<\/jats:styled-content> tumors were positive for GM<\/jats:styled-content>2, with individual variation in the intensity and frequency of staining. These data suggest that anti\u2010GM<\/jats:styled-content>2 antibodies may become a therapeutic option for MPM<\/jats:styled-content> patients.<\/jats:p>","DOI":"10.1111\/cas.12575","type":"journal-article","created":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T05:42:54Z","timestamp":1416894174000},"page":"102-107","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic activity of glycoengineered anti\u2010GM<\/scp>2 antibodies against malignant pleural mesothelioma"],"prefix":"10.1111","volume":"106","author":[{"given":"Qi","family":"Li","sequence":"first","affiliation":[{"name":"Division of Medical Oncology Cancer Research Institute Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Cancer Research Institute Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Machino","sequence":"additional","affiliation":[{"name":"Oncology Research Laboratories R&D Division Kyowa Hakko Kirin Co., Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Cancer Research Institute Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kita","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Cancer Research Institute Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Genetics Cancer Research Institute Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology Aichi Cancer Center Research Institute Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"CNS Research Laboratories R&D Division, Kyowa Hakko Kirin Co., Ltd. Shizuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Translational Research Unit R&D Division Kyowa Hakko Kirin Co., Ltd. Shizuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken\u2010ichiro","family":"Nan\u2010ya","sequence":"additional","affiliation":[{"name":"Translational Research Unit R&D Division Kyowa Hakko Kirin Co., Ltd. Shizuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Iida","sequence":"additional","affiliation":[{"name":"Research Core Function Laboratories R&D Division Kyowa Hakko Kirin Co., Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyasu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Tokyo Research Park R&D Division Kyowa Hakko Kirin Co., Ltd. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Iwakiri","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Hyogo Prefectural Amagasaki Hospital Amagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Itoi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Hyogo Prefectural Amagasaki Hospital Amagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Cancer Research Institute Kanazawa University Kanazawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"1053","article-title":"Demographic patterns for mesothelioma in the United States","volume":"78","author":"Connelly RR","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480601300402"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.8.1157"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02306613"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(19)36577-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1607"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01222.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8957"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq585"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010999014657"},{"key":"e_1_2_7_13_1","first-page":"7444","article-title":"Glycosphingolipids of human gliomas","volume":"50","author":"Jennemann R","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_7_14_1","first-page":"2405","article-title":"Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives","volume":"45","author":"Hakomori S","year":"1985","journal-title":"Cancer Res"},{"key":"e_1_2_7_15_1","first-page":"249","article-title":"Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen","volume":"66","author":"Jones PC","year":"1981","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.9303"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00006689"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.02093.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp097"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<170::AID-IJC8>3.0.CO;2-Y"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.4049\/jimmunol.147.7.2222","article-title":"A novel monoclonal antibody against murine IL\u20102 receptor beta\u2010chain. Characterization of receptor expression in normal lymphoid cells and EL\u20104 cells","volume":"147","author":"Tanaka T","year":"1991","journal-title":"J Immunol"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00163.x"},{"key":"e_1_2_7_23_1","first-page":"1511","article-title":"Chimeric anti\u2010ganglioside GM2 antibody with antitumor activity","volume":"54","author":"Nakamura K","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0881-6"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01463.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300448"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018198"},{"key":"e_1_2_7_28_1","first-page":"271","article-title":"Comparative dual label study of first and second generation antitumor\u2010associated glycoprotein\u201072 monoclonal antibodies in colorectal cancer patients","volume":"53","author":"Gallinger S","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000811"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.10.054"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242783"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050152"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12575","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.12575","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:54:32Z","timestamp":1696298072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/cas.12575"],"URL":"https:\/\/doi.org\/10.1111\/cas.12575","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}